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Abstract
Background: Oral (p.o.) chemotherapy treatments gained increasing importance in the palliative treatment of
metastatic breast cancer (MBC). Aim of this survey was to evaluate the acceptance of p.o. treatment and patients’
individual attitudes towards it.
Methods: A specific 14 item-questionnaire was designed. Patients suffering from breast cancer receiving a newly
launched p.o. or i.v. chemotherapy treatment were prospectively evaluated during 4 months of time. 224
questionnaires using descriptive statistics, chi-square test, Spearman correlation were evaluated.
Results: Patients’ median age was 54 years, 164 received i.v., 60 p.o therapy. 89% with p.o. and 67% with i.v.
regimens would choose p.o. over i.v. therapy, if equal efficacy is guaranteed. Significant differences were especially
found in terms of personal benefit (55% i.v., 92% p.o.), reduced feeling of being ill due to p.o. treatment (26% i.v.,
65% p.o.), better coping with disease due to p.o. therapy (36% i.v., 68% p.o.). Side effects were significantly less
often reported under p.o. treatment (19% p.o. vs. 53% i.v.).
Conclusion: P.o. chemotherapy shows a high acceptance in MBC patients under palliative therapy. Compliance
can be achieved in particular through a differentiated indication, patient education and competent support along
a p.o. treatment.
Background
Breast cancer is the leading neoplastic malignancy among
women worldwide affecting one in 8 women [1]. Its inci-
dence is steady and so is the number of patients under ther-
apy with a chronic metastatic disease [2,3]. Therefore, the
search for new innovative chemotherapeutic standards is
ongoing. On the one hand, facing the demand to develop
new drugs with higher antitumor activity and lower sys-
temic toxicity [3]. On the other hand aiming to find drugs
that control cancer as a chronic process and match require-
ments of a convenient long term application with high
quality of life [4-6]. Conventional anticancer chemotherapy
is dominated by complex intravenous (i.v.) regimes which
affect patients’ life considerably [7-9]. Not only the substan-
tial amount of time spent for the treatment as such places a
major burden on patients but also the frequent placement
of indwelling catheters and its associated fears or severe
complications [10-12]. Thus, the development of an oral
(p.o.) anticancer therapy has been in focus over the past few
years [13-17] and has also been evaluated in all-oral combi-
nation regimes [18]. Oral chemotherapy offers several bene-
fits in terms of convenience, ease of administration,
improved quality of live and economic aspects [9,19-23].
Previous surveys and studies have addressed the accep-
tance of oral chemotherapy among patients and health
care professionals [24,25]. These results revealed that most
patients, who had experienced p.o. therapy, favor p.o. over
i.v. chemotherapy [8,19,24-30]. Since these data have been
published an increasing number of oral chemotherapeutics
have been licensed and approved and will find their way in
adjuvant therapies. Our survey study investigates breast
cancer patients’ personal concerns, doubts and general feel-
ings towards p.o. application as well as the patient’sr e a s o n s
for preferring a p.o. or an i.v. treatment in the adjuvant as
well as palliative setting. The assessment of the study pro-
vides insights for health care professionals on patient orien-
tated education as well as guidelines to obtain a high
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offers important information on patient desires as well as
on prejudices that have to be taken into account when
establishing oral chemotherapy as an alternative standard
to i.v. treatment in palliative as well as adjuvant setting.
Methods
Patients
This study was conducted in accordance with the ethical
principals laid down in the Declaration of Helsinki and
the International Conference on Good Clinical Practice.
The study protocol was approved by the Ethics Com-
mittee of the University of Heidelberg. All patients pro-
vided written informed consent before study entry.
Patients were eligible if they were ≥18 years old, had
histologically confirmed breast cancer, currently either
under i.v. or oral chemotherapy and if they provided
written informed consent before in-clusion. Patients
who had only received a prior hormonal therapy or
those being not legally capable could not be included.
Concomitant hormonal chemotherapy was not allowed.
Questionnaire
The data published by Catania at al. [24] on the percep-
tion of oral chemotherapy and recent steps in p.o. drug
development (covering MEDLINE results from 1969 to
2008) provided the basis for the preparation of our ques-
tionnaire [Additional file 1]. Their described validated
questionnaire was transformed to our institutional stan-
dards and translated into German language (appendix 1).
It evaluates the acceptance of p.o. versus. i.v. chemother-
apy based on three different levels, focusing on personal,
functional and tolerability-/efficacy-associated aspects.
Statistical analysis
The absolute and relative frequencies with regard to the
available response categories/response options were eval-
uated overall and differentiated by p.o. and i.v. treatment;
this evaluation included the analysis of missing answers.
For each of the questions 1-9 the frequency-distribution
over the response-categories was analyzed graphically.
The correlation of responses between questions 1 to 9
was assessed pairwise using the Spearman’sr a n kc o e f f i -
cient. The association between two categorical variables
was analyzed using the c-squared test. Potential differ-
ences in patients’ responses according to age group and
route of administration were also examined using
c-squared test. Level of significance a was set to 5%.
Results
Patient characteristics
224 patients completed the questionnaire. 164 (73.2%)
and 60 (26.8%) patients received i.v. and p.o. chemother-
apy, respectively.
95 (57.9%) and 10 (6.1%) of the i.v. treated patients
received the observed treatment in adju-vant and neoad-
juvant setting, respectively. The remaining 59 (36.0%)
patients were treated with palliative intent. Women
undergoing palliative treatment were pretreated with a
median of 3 prior systemic anticancer regimens in the
oral group and 4.0 in the i.v. group. 20 (12.2%) patients
of the i.v. group had experienced oral chemotherapy
before, 12 (20.0%) of the p.o., respectively.
All 60 (100%) patients of the p.o. treated group
received the observed treatment in palliative setting.
These patients were pretreated with a median of 3.0
prior systemic anticancer regimens. 12.0 (20.0%) patients
had already experienced oral chemotherapy before. 39
(65.0%), 17 (28.3%), 4 (6.7%) of the p.o. group were
undergoing monochemotherapy, combination with i.v.
or combination with another p.o. agents at the time of
observation, respectively.
T h em e a na g eo ft h et o t a ls t u d i e dp o p u l a t i o nw a s
53 years (i.v. 52.6 years; p.o. 55.6 years), most patients
graduated from middle school, were married and non-
working. There were no relevant differences between
the two treatment groups. Table 1 provides an overview
on the main patient charac-teristics.
Questionnaire
In total 224 patients answered the questionnaire cor-
rectly (i.v.: 164; p.o.: 60), with analyzable answers per
question ranging from 212 to 224 (i.v.: 155-164; p.o.:
56-60; see Table 2 and Figure 1, 2, 3, 4, 5, 6, 7, 8, 9).
Question 1 to 9 showed a broad range of answers as
displayed in the bar graphs provided in Figures 1, 2, 3,
4, 5, 6, 7, 8, 9. Partially significant differences were
observed between the p.o. and i.v. group (Table 2). 48
patients documented free-text com-ments (question 14)
providing additional explanations. Regarding questions
12 and 13 over 50% of cases were answered in an invalid
way, so data from these questions are not analyzed.
Personal aspects
Patients’ personal benefits were addressed with ques-
tions 1, 4 and 7.
In the overall population, including oral and i.v. trea-
ted patients; there was a tendency in favor of oral treat-
ment with regard to the question, if the patient sees a
personal benefit when receiving oral instead of i.v. treat-
ment (Figure 1). This direct personal benefit due to oral
chemotherapy was judged with a significant difference
between both groups (p < 0.0001). Over half (58.3%) of
the patients receiving p.o. treatment expected a clear
benefit from the oral application form; while the corre-
sponding percentage was 28.6% in the i.v. population
(Table 2 - question 1).
The impact on everyday life due to clinical visits and
hospitalizations caused by i.v. treatment (question 7)
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patients describing a medium to strong impact (cate-
gories 3+4: i.v.: 58.4%; p.o.: 62.5%); there was no signifi-
cant difference between the administration routes (Table
2 - question 7). Moreover, there were no age-depending
differences below or above 50 years within this group, if
age was set as point of interest (data not shown). The
overall population tended to see a moderate impact on
the everyday life due to i.v. associated hospital visits
(Figure 2).
The question whether daily and family life is impacted
less by p.o. than by i.v. chemotherapy (question 4)
revealed a significant difference (p < 0.0074) between
the two treatment groups. In both groups a relevant
percentage of patients believed in less disturbances due
to p.o. treatment (p.o.: 36.7%; i.v.: 24.4%; Table 2 - ques-
tion 4). While in the i.v. population 23.2% did not
expect a relevant benefit from p.o. treatment with regard
to their daily life, such response was obtained in only
8.3% in the p.o. population.
Functional aspects
The question how functional aspects in terms of coping
with the disease are influenced by the application form
was assessed (questions 8 and 9).
Question 8 addressed how therapeutic application
could support the coping with disease in ge-neral. The
overall population did not show a clear trend (Figure
Table 1 Baseline characteristics (N = 224)
(N, % of group) i.v. p.o.
Number of participants 164 60
Mean age in years (range) 52.6 (30 - 76) 55.8 (26 - 81)
Treatment at the time of observation
Neoadjuvant 10 (6.1%) 0
Adjuvant 95 (57.9%) 0
Palliative 59 (36.0%) 60 (100%)
Prior treatments
Prior p.o. treatment 20 (12.2%) 12 (20.0%)
Number of prior systemic anticancer
regimens when treated in palliative
intent [mean (range)]
4.0 (1 - 9) 3.0 (1 - 10)
Level of education
Lower school 43 (26.2%) 15 (25.0%)
Middle school 69 (42.1%) 25 (41.7%)
High school 21 (12.8%) 7 (11.7%)
University graduation 29 (17.7%) 13 (21.7%)
Missing information 2 (1.2%) 0
Active employment 62 (37.8%) 20 (33.3%)
Marital status
Unmarried 33 (20.1%) 12 (20.0%)
Married 123 (75.0%) 42 (70.0%)
Widowed 8 (4.9%) 6 (10.0%)
Table 2 Results of Questions 1 - 9
Question No. Therapyform N evaluable patients 1
not at all
234
very much
p-value
1 i.v. 161 22.98 22.36 26.09 28.57 <0.0001
p.o. 60 3.33 5.00 33.33 58.33
2 i.v. 162 35.80 38.27 20.37 5.56 <0.0001
p.o. 60 16.67 18.33 36.67 28.33
3 i.v. 163 65.03 17.18 10.43 7.36 0.0757
p.o. 60 80.00 11.67 8.33 0.00
4 i.v. 164 23.17 20.12 32.32 24.39 0.0074
p.o. 60 8.33 10.00 45.00 36.67
5 i.v. 155 7.10 29.68 43.87 19.35 <0.0001
p.o. 57 1.75 5.26 43.86 49.12
6 i.v. 160 40.63 40.63 13.13 5.63 <0.0001
p.o. 59 22.03 25.42 27.12 25.42
7 i.v. 161 21.12 20.50 39.75 18.63 0.5605
p.o. 56 16.07 21.43 35.71 26.79
8 i.v. 163 36.81 26.99 22.09 14.11 <0.0001
p.o. 59 8.47 23.73 35.59 32.20
9 i.v. 164 23.78 23.17 28.05 25.00 0.0005
p.o. 58 6.90 10.34 34.48 48.28
[% of patients in the i.v. (N = 164) and p.o. (N = 60) population].
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Page 3 of 104). 32.2% of the p.o. group saw a clear benefit due to
oral chemotherapy; whereas only 8.5% expected no
support at all through oral medication. A significant
difference was observed when comparing the p.o. and
i.v. groups (p < 0.0001). 36.8% of the i.v. treated
patients did not see any positive aspect by p.o. che-
motherapy with regard to better coping with breast
cancer; only 14.1% strongly believed in a better coping
when using orally administered drugs (Table 2 - ques-
tion 8).
Question 9, asking if oral chemotherapy would make
it easier for the patient to handle her disease by
p r o v i d i n gm o r ea u t o n o m yo u t s i d et h ec l i n i c ,a l s o
showed a significant difference between both therapy
groups (p = 0.0005). 48.3% of the patients with p.o.
treatment believed in a better handling of their disease
due to p.o. application. On the opposite, only 25.0% of
the i.v. treated patients claimed a clear benefit by p.o.
chemotherapy (Table 2 - question 9). The overall popu-
lation slightly tended to expect more autonomy due to
oral treatment (Figure 5).
Tolerability- and efficacy-associated aspects
Tolerability- and efficacy-associated aspects were
addressed with questions 2, 3, 5 and 6.
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Figure 1 Question 1: Do you see a personal benefit receiving
oral instead of i.v. treatment? (evaluable patients; N = 221).
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Figure 2 Question 7: To which extend has your everyday life
been affected in the past by hospital visits performed
especially due to i.v. administration of chemotherapy?
(evaluable patients; N = 217).
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Figure 3 Question 4: Do you believe that an oral
chemotherapy affects your everyday life and your family
surrounding less than an i.v. chemotherapy? (evaluable
patients; N = 224).
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Figure 4 Question 8: Do you believe than an oral
chemotherapy could make it easier for you to cope with your
disease? (evaluable patients; N = 222).
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believe in feeling less ill under oral compared to i.v.
treatment (Figure 6). There was a significantd i f f e r e n c e
in patients’ subjective per-ception with regard to feeling
less ill when treated orally or intravenously (p < 0.0001).
While the i.v. patients tended to respond that oral treat-
ment will not help them in coping with their disease,
oral patients claimed a benefit from oral treatment
(categories 3+4: i.v.: 25.9%; p.o.: 65.0%; Table 2 - ques-
tion 2).
The perceptions concerning lower side effects under p.
o. chemotherapy were again signifi-cantly diverse
between both groups (p < 0.0001). Patients’ opinions
varied broadly within the p.o. treated group as such;
22.0% believed that there is no reduction of side effects
due to p.o. chemotherapy while 25.4% expect such
reduction. The i.v. treated patients were more skeptical:
40.6% did not expect reduction of side effects under oral
treatment with only 5.6% being opposed to this opinion
(Table 2 - question 6). In the overall population the
majority of patients tended not to believe in fewer side
effects due to oral administration (Figure 7).
A significant variation was assessed between both
groups in terms of creed towards equal ef-ficacy of p.o.
%
0
10
20
30
40
1234
EŽƚĂƚĂůů sĞƌǇŵƵĐŚ
Figure 5 Question 9: Do you think that a chemotherapy with
capsules or tablets would make it easier for you to handle
your disease by giving you more autonomy outside the clinic?
(evaluable patients; N = 222).
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Figure 6 Question 2: Do you believe that you feel less ill when
receiving oral instead of i.v. chemotherapy? (evaluable
patients; N = 222).
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Figure 7 Question 6: Do you believe that an oral
chemotherapy has less side effects than an i.v. chemotherapy?
(evaluable patients; N = 219).
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Figure 8 Question 5: Do you believe that an oral
chemotherapy is as effective as an i.v. chemotherapy?
(evaluable patients; N = 212).
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Page 5 of 10and i.v. drugs (p < 0.0001). Patients under oral treat-
ment strongly believed in equal efficacy (49.1%). A
major part of the patients receiving i.v. chemotherapy
also assumed that there is an equivalent efficacy (cate-
gory 3: 43.9%, category 4: 19.4%), however, also 29.7%
(rank 2) of these patients were more opposed to this
opinion (Table 2 - question 5). In the overall population
the majority of patients tended to assume that there is
an equivalent efficacy (Figure 8).
Correct intake of p.o. chemotherapy is a major issue
for successful treatment. 80.0% of the p.o. and 65.0% of
the i.v. treated patients were not concerned about a
wrong intake (Table 2 - question 3). Therefore, the
trend in the overall population was clear towards no
hesitation about oral intake (Figure 9). Interestingly,
there was no difference between the age groups if an
age of 50 was set as a cutoff (data not shown); thus,
elderly patients are not more reserved towards p.o. che-
motherapy than the young.
Patients’ preference and source of information
If patients could choose between an equally effective p.o.
or i.v. application, 89.3% of the orally treated women
would again choose p.o. treatment. Also 67.1% of those
patients receiving i.v. treatment would prefer p.o.
medication.
The patients specified the following sources with
regard to information about the disease and treatment
options: physicians (97.7%), internet (38.8%), second opi-
nions (23.6%) and relatives (16.9%); there were no signif-
icant differences between both groups.
Correlations
The correlations between answers given to any set of
two of the questions 1 to 9 was explored using the
Spearman rank coefficient (Table 3). This analysis was
not adjusted for multiple comparisons. Most of the cor-
relations revealed significant p-values and - taken the
low magnitude of the observed p-values - it is very likely
that these would still reach the level of significance, even
if adjustment for multiple comparisons would have been
performed. Moderate correlations (r ≥ 0.4) were found
for questions 1, 2, 4, 5, 6, 8 and 9. The largest coeffi-
cients (bold in Table 3) were found between questions 8
and 9 (r = 0.64), 1 and 8 (r = 0.62) as well as questions
4 and 9 (r = 0.60). Specifically, patients who strongly
believed that oral chemotherapy could make it easier for
them to cope with their disease (question 8) tended to
strongly agree with the point that such chemotherapy
would make it easier for the patients to handle their dis-
ease by providing more autonomy outside the clinic
(question 9).
Discussion
Breast cancer - with its high incidence worldwide -
requires effective treatment options with high practic-
ability, selectivity and tolerability. At present most ther-
apy options are complex i.v. treatments, being usually
connected with traveling efforts, time-consuming hospi-
tal-procedures and high costs [23,31-33]. In contrast, p.
o. chemotherapy can easily be applied in an out-patient
setting, e.g. in cooperation with the patient’s general
practitioner, thus reducing hospital visits and burden-
some invasive medical procedures, such as placements
of catheters. It was already demonstrated that, with oral
treatment, the time spend in hospital as well as the
overall costs of chemotherapy can be reduced consider-
ably [13].
However, patients’ and health care professionals’ skep-
ticism towards p.o. treatment has been observed
[9,11,19,24,26,34-36]. Hesitations towards p.o. drug pre-
scriptions mainly resulting from apprehensions regard-
ing bioavailability, doubts about efficacy, and concerns
about compliance initially hampered the development of
p.o. anticancer drugs [26,37]. In addition, patients some-
t i m e sb e l i e v e dt h a tp . o .d r u g sa r ep r e s c r i b e da sl a s t
resort [24]. In the meanwhile, results from various stu-
dies contributed to the resolution of such prejudices
and led to considerable progress in the development of
oral treatment options [13,14,16,17] as well as of all-oral
chemotherapy combinations [9,26,38-40].
When talking about oral chemotherapy, the therapy
course and the therapeutically success first of all depend
on patient-independent factors such as bioavailability,
side effect profile (e.g. gastrointestinal toxicity) and opti-
mal dosing schedules. Oral treatments face additional
pathways such as gastrointestinal passage and first-pass
effects in comparison to i.v. treatments and thus require
specific knowledge of healthcare professionals [26]. The
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Figure 9 Question 3: Are you afraid that - in case of an oral
chemotherapy - you could eventually take the capsules/tablets
in a wrong way? (evaluable patients; N = 223).
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Page 6 of 10development of modern oral chemotherapies led to oral
treatment options with adequate pharmacokinetic prop-
erties, acceptable side effect profiles and high efficacy
[16,38,40-44].
Since 2005, when Catania et al. assessed patients’ per-
ceptions on efficacy of p.o. therapy, several oral agents
have been licensed for breast cancer treatment and
gained acceptance in this indication [30]. Based on the
above mentioned efforts in oral drug development,
initial reservation is increasingly obsolete and usage of
p.o. treatment has grown. Among our interviewed
patients, 9 out of 10 being treated orally and 7 out of 10
being treated intravenously would prefer p.o. over i.v.
treatment if same efficacy is ensured. This is in agree-
ment with the data of Liu et al, who also reported a
high patient preference (89%) for p.o. treatment [19].
Other studies involving patients having experienced p.o.
and i.v. treatment within the respective trial revealed
patient preferences of 39% [45], 64% [20], 74% [25], 84%
[46] and 90% [47]. Moreover, our survey revealed that
the majority of patients in the p.o. and the i.v. group
believed in equal efficacy of both routes of administra-
tion. However, p.o. treated patients trusted more in oral
therapy than those under i.v. treatment, leading to a sig-
nificant difference between both groups; in the i.v.
group approximately 1/3 of patients still were of the
opinion that i.v. drugs generally provide higher efficacy.
Presumably, unfamiliarity with p.o. treatment led to
these hesitations.
Commercial availability of active p.o. drugs will not
directly ensure their use [26]. It is known that patients’
compliance may still to some extent be hampered by
general prejudices and incertitude con-cerning correct
usage of the medication. Thus, oral chemotherapy will
only be effective if compliance is optimized. For that
reason, the ability of patients to understand the treat-
ment in general, the specifics of an oral chemotherapy
and the treatment schedule are key issues for a success-
ful p.o. therapy. Our survey showed that the treating
physicians still represent the main source for such treat-
ment information, emphasizing their role for a correct
therapy run. Data have shown that patients with p.o.
chemotherapy treatments are generally motivated to
ensure intake of their treatment [48,49]. Comparing
recent studies (2000 - 2009) to those from the early 90’s
clear improvements in patient compliance have been
observed [49]. An understandable treatment regimen
and the use of patient dairies can reduce misunder-
standings or wrong intakes [50,51]. Detailed information
on side effect profiles (e.g. using patient information
leaflets) and on requirements for treatment adaptations
enable patients to contribute to the treatment and give
them a greater sense of personal responsibility [26].
The impact of i.v.-treatment-related hospital visits on
everyday life has been mentioned to be a major factor
influencing quality of life [24]. In both treatment groups
investigated in our survey the majority of patients
agreed that oral treatment contributes to a better quality
of life; especially those women who had experienced p.o.
treatment confirmed a clear benefit (i.v.: 43%; p.o.: 63%).
We assumed that especially younger women with young
children would prefer p.o. therapy, however - consistent
with the results of Catania et al. - no significant age-
depended differences could be observed [24].
Table 3 Correlation between item 1 through 9 in the questionnaire
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
Q1 1.00000 0.57534
<.0001
0.26799
<.0001
0.53925
<.0001
0.43413
<.0001
0.36976
<.0001
0.34612
<.0001
0.61854
<.0001
0.55128
<.0001
Q2 1.00000 0.27215
<.0001
0.44921
<.0001
0.22798
<.0001
0.45738
<.0001
0.31618
<.0001
0.54728
<.0001
0.48659
<.0001
Q3 1.00000 0.05066
0.2857
0.19717
<.0001
0.18867
<.0001
0.08223
0.0878
0.18750
<.0001
0.28425
<.0001
Q4 1.00000 0.18743
0.0001
0.21409
<.0001
0.37361
<.0001
0.44632
<.0001
0.59938
<.0001
Q5 1.00000 0.23208
<.0001
0.18818
0.0001
0.35262
<.0001
0.34081
<.0001
Q6 1.00000 0.10478
0.0310
0.34833
<.0001
0.26770
<.0001
Q7 1.00000 0.36320
<.0001
0.39544
<.0001
Q8 1.00000 0.63656
<.0001
Q9 1.00000
Spearman Correlation Coefficients.
Prob > |r| under H0: Rho = 0.
Q = question.
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analyzed with our survey revealed significant differ-
ences between the p.o. and i.v. group, indicating that
prior treatment experience guides the acceptance of
oral vs. intravenous therapy. This is also true with
regard to the coping and handling of the disease.
Approximately 50% of the women with p.o. treatment
saw a clear benefit due to personal freedom and the
possibility of self-management by p.o. application.
Some women stated that a p.o. treatment gives them
the feeling of a chronic instead of a life-threatening
disease and allows them a better coping with the dis-
ease. The i.v. treated population was more skeptic.
Some of the patients who had not yet experienced p.o.
chemotherapy stated that they would miss the personal
contact to other patients, the peer group benefit as
well as the frequent interaction with the medical team.
Most patients appreciated however, the possibility to
reduce the daily presence of their disease by using oral
treatment combined with a close connection to the
centre and the availability of supporting staff via phone
or out-patient clinic if required. The importance of
this infrastructural setting was emphasized before [24].
It is important to mention that especially patients
under adjuvant or neoadjuvant treatment stated that
confrontation with other patients in a more progressed
status of disease causes high emotional involvement;
therefore such patients often prefer a home-based
treatment. Also to mention the institutional triggered
side effects such as psychogenic nausea along with
institution-induced vomiting that considerably reduces
q u a l i t yo fl i f ea n do f t e ns e e m st og e tw o r s ew i t hl o n g e r
duration of palliative i.v. chemotherapy. Those negative
issues are not relevant when using p.o. chemotherapy.
In general, the major benefit of oral versus i.v. che-
motherapy can be described with a broader flexibility
e n a b l i n gam o r ei n d i v i d u a l i z e dt h e r a p ya n dah i g h e r
quality of life. However, the amount of tablets or cap-
sules needed to be swallowed has to be taken into
account. Compliance can be lower if patients have to
swallow numerous tablets every day [34,35] and studies
have shown that a daily intake of maximum 6-8 tablets
is acceptable [9]. This finding should be taken into
account in the future development of oral drugs. One
example of such development are so called duplex
drugs, establishing a chemical link between two highly
active anticancer compounds and resulting in a new,
mono-molecule’ [52].
Conclusion
Oral chemotherapy plays an increasing role in breast
cancer therapy. So far, it has mainly be-en used in pal-
liative setting, however it will gain its place additionally
in adjuvant settings as the PARPi inhibitors will show.
High efficacy, adequate tolerability, acceptable bioavail-
ability with low inter- and intra-individual variability
and a limited number of tablets/capsules per day are
basic prerequisites and have been limiting factors for
oral drug development. When fulfilling these require-
ments, oral treatment can contribute to an improvement
of the patients’ quality of life, which remains high prior-
ity especially in metastatic disease. Nevertheless, suc-
cessful oral therapy requires compliance. Thus, a
differentiated indication as well as a detailed patient-
oriented education and explanation of the p.o. treatment
schedule, including information on potential side effects,
are key factors for a successful treatment.
Additional material
Additional file 1: Questionnaire. The questionnaire used for this survey
is shown.
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